Innate immunity and cancer therapy

International Immunopharmacology

Volumn 11, Issue 3, 2011, Pages 350-357

  Maruyama, Kouji ^a   Selmani, Zohair ^a   Ishii, Hidee ^a   Yamaguchi, Ken ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

Author keywords

Biological response modifiers; Cancer therapy; Innate immunity; Toll like receptors

Indexed keywords

AGATOLIMOD; IMIQUIMOD; RESIQUIMOD; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 9 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ANTIGEN RECOGNITION; ANTINEOPLASTIC ACTIVITY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CARCINOGENESIS; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; HOMEOSTASIS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS;

EID: 79952105503     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2010.09.012     Document Type: Review

References (133)

1. Rakoff-Nahoum S, Medzhitov R. Toll-like receptors and cancer. Nat Rev Cancer 2009;9:57-63.
2. Garay RP, Viens P, Bauer J, Normier G, Bardou M, Jeannin JF, et al. Cancer relapse under chemotherapy: Why TLR2/4 receptor agonists can help. Eur J Pharmacol 2007;563:1-17. (Pubitemid 46628799)
3. Tsung K, Norton JA. Lessons from Coley's toxin. Surg Oncol 2006;15:25-8.
4. + T-cells in the antitumor activity of an immunomodulator, SSM, extracted from human-type Tubercle bacilli. J Natl Cancer Inst 1986;77:441-7.
5. Suzuki F, Brutkiewicz RR, Pollard RB. Lack of correlation between antitumour response and serum interferon levels in mice treated with SSM, an immunotherapeutic anticancer agent. Br J Cancer 1986;53:567-70. (Pubitemid 16111977)
6. Sasaki H, Schmitt D, Hayashi Y, Pollard RB, Suzuki F. Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted from Mycobacterium tuberculosis. Cancer Res 1990;50:4032-7. (Pubitemid 20225626)
7. Akiyama J, Kawamura T, Gotohda E, Yamada Y, Hosokawa M, Kodama T, et al. Immunochemotherapy of transplanted KMT-17 tumor in WKA rats by combination of cyclophosphamide and immunostimulatory protein-bound polysaccharide isolated from basidiomycetes. Cancer Res 1977;37:3042-5. (Pubitemid 8169955)
8. Mizushima Y, Yuhki N, Hosokawa M, Kobayashi H. Diminution of cyclophosphamide-induced suppression of antitumor immunity by an immunomodulator PS-K and combined therapeutic effects of PS-K and cyclophosphamide on transplanted tumor in rats. Cancer Res 1982;42:5176-80. (Pubitemid 13223165)
9. Kai S, Tanaka J, Nomoto K, Torisu M. Studies on the immunopotentiating effects of a streptococcal preparation, OK-432 I: Enhancement of T cell-mediated immune responses of mice. Clin Exp Immunol 1979;37:98-105.
10. Kataoka T, Oh-hashi F, Sakurai Y. Immunotherapeutic response of concanavalin A-bound L1210 vaccine enhanced by a streptococcal immunopotentiator, OK-432. Cancer Res 1979;39:2807-10. (Pubitemid 9204234)
11. Tsuji S, Matsumoto M, Takeuchi O, Akira S, Azuma I, Hayashi A, et al. Maturation of human dendritic cells by cell wall skeleton of Mycobacterium bovis bacillus Calmette-Guérin: Involvement of Toll-like receptors. Infect Immun 2000;68: 6883-90. (Pubitemid 32463398)
12. Azuma I, Ribi EE, Meyer TJ, Zbar B. Biologically active components from mycobacterial cell walls I: Isolation and composition of cell wall skeleton and component P3. J Natl Cancer Inst 1974;52:95-101.
13. Hayashi A, Nishida Y, Yoshii S, Kim SY, Uda H, Hamasaki T. Immunotherapy of ovarian cancer with cell wall skeleton of Mycobacterium bovis Bacillus Calmette-Guérin: Effect of lymphadenectomy. Cancer Sci 2009;100:1991-5.
14. Kodama K, Higashiyama M, Takami K, Oda K, Okami J, Maeda J, et al. Innate immune therapy with a Bacillus Calmette-Guérin cell wall skeleton after radical surgery for non-small cell lung cancer: A case-control study. Surg Today 2009;39:194-200.
15. Hashimoto C, Hudson KL, Anderson KV. The Toll gene of Drosophila, required for dorsal-ventral embryonic polarity, appears to encode a transmembrane protein. Cell 1988;52:269-79.
16. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-83. (Pubitemid 26336801)
17. Medzhitov R, Preston-Hurlburt P, Janeway Jr CA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-7. (Pubitemid 27334820)
18. Takeda K, Kaisho T, Akira S. Toll-like receptors.Annu Rev Immunol 2003;21:335-76.
19. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004;10:987-95. (Pubitemid 41057715)
20. van Noort JM, Bsibsi M. Toll-like receptors in the CNS: Implications for neurodegeneration and repair. Prog Brain Res 2009;175:139-48.
21. Li X, Jiang S, Tapping RI. Toll-like receptor signaling in cell proliferation and survival. Cytokine 2010;49:1-9.
22. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: Heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000;164:558-61. (Pubitemid 30043672)
23. Vabulas RM, Ahmad-Nejad P, da Costa C, Miethke T, Kirschning CJ, Häcker H, et al. Endocytosed HSP60s use toll-like receptor 2 (TLR2) and TLR4 to activate the Toll/interleukin-1 receptor signaling pathway in innate immune cells. J Biol Chem 2001;276:31332-9. (Pubitemid 37385004)
24. Vabulas RM, Ahmad-Nejad P, Ghose S, Kirschning CJ, Issels RD, Wagner H. HSP70 as endogenous stimulus of the Toll/interleukin-1 receptor signal pathway. J Biol Chem 2002;277:15107-12. (Pubitemid 34952589)
25. Asea A, Rehli M, Kabingu E, Boch JA, Bare O, Auron PE, et al. Novel signal transduction pathway utilized by extracellular HSP70: role of toll-like receptor (TLR) 2 and TLR4. J Biol Chem 2002;277:15028-34. (Pubitemid 34952579)
26. Dybdahl B, Wahba A, Lien E, Flo TH, Waage A, Qureshi N, et al. Inflammatory response after open heart surgery: Release of heat-shock protein 70 and signaling through Toll-like receptor-4. Circulation 2002;105:685-90. (Pubitemid 34157370)
27. Vabulas RM, Braedel S, Hilf N, Singh-Jasuja H, Herter S, Ahmad-Nejad P, et al. The endoplasmic reticulum-resident heat shock protein Gp96 activates dendritic cells via the Toll-like receptor 2/4 pathway. J Biol Chem 2002;277:20847-53. (Pubitemid 34967392)
28. Roelofs MF, Boelens WC, Joosten LA, Abdollahi-Roodsaz S, Geurts J, Wunderink LU, et al. Identification of small heat shock protein B8 (HSP22) as a novel TLR4 ligand and potential involvement in the pathogenesis of rheumatoid arthritis. J Immunol 2006;176:7021-7. (Pubitemid 43787883)
29. Park JS, Gamboni-Robertson F, He Q, Svetkauskaite D, Kim JY, Strassheim D, et al. High mobility group box 1 protein interacts with multiple Toll-like receptors. Am J Physiol Cell Physiol 2006;290:C917-24.
30. Park JS, Svetkauskaite D, He Q, Kim JY, Strassheim D, Ishizaka A, et al. Involvement of toll-like receptors 2 and 4 in cellular activation by high mobility group box 1 protein. J Biol Chem 2004;279:7370-7. (Pubitemid 38294612)
31. Liu-Bryan R, Scott P, Sydlaske A, Rose DM, Terkeltaub R. Innate immunity conferred by Toll-like receptors 2 and 4 and myeloid differentiation factor 88 expression is pivotal to monosodium urate monohydrate crystal-induced inflammation. Arthritis Rheum 2005;52:2936-46. (Pubitemid 41372129)
32. Liu-Bryan R, Pritzker K, Firestein GS, Terkeltaub R. TLR2 signaling in chondrocytes drives calcium pyrophosphate dihydrate and monosodium urate crystal-induced nitric oxide generation. J Immunol 2005;174:5016-23. (Pubitemid 40514462)
33. Guillot L, Balloy V, McCormack FX, Golenbock DT, Chignard M, Si-Tahar M. Cutting edge: the immunostimulatory activity of the lung surfactant protein-A involves Toll-like receptor 4. J Immunol 2002;168:5989-92. (Pubitemid 34620010)
34. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001;276: 10229-33.
35. Johnson GB, Brunn GJ, Kodaira Y, Platt JL. Receptor-mediated monitoring of tissue well-being via detection of soluble heparan sulfate by Toll-like receptor 4. J Immunol 2002;168:5233-9. (Pubitemid 34495991)
36. Schaefer L, Babelova A, Kiss E, Hausser HJ, Baliova M, Krzyzankova M, et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J Clin Invest 2005;115:2223-33. (Pubitemid 41134165)
37. Smiley ST, King JA, Hancock WW. Fibrinogen stimulates macrophage chemokine secretion through toll-like receptor 4. J Immunol 2001;167:2887-94. (Pubitemid 32768923)
38. Termeer C, Benedix F, Sleeman J, Fieber C, Voith U, Ahrens T, et al. Oligosaccharides of Hyaluronan activate dendritic cells via Toll-like receptor 4. J Exp Med 2002;195:99-111. (Pubitemid 34074500)
39. Jiang D, Liang J, Fan J, Yu S, Chen S, Luo Y, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med 2005;11:1173-9. (Pubitemid 43093664)
40. Gurtner GC, Werner S, Barrandon Y, Longaker MT. Wound repair and regeneration. Nature 2008;453:314-21. (Pubitemid 351693137)
41. Kluwe J, Mencin A, Schwabe RF. Toll-like receptors, wound healing, and carcinogenesis. J Mol Med 2009;87:125-38.
42. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS, et al. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology 2006;131:862-77. (Pubitemid 44316821)
43. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell 2004;118:229-41. (Pubitemid 38962578)
44. Tsung A, Sahai R, Tanaka H, Nakao A, Fink MP, Lotze MT, et al. The nuclear factor HMGB1 mediates hepatic injury after murine liver ischemiareperfusion. J Exp Med 2005;201:1135-43. (Pubitemid 40524681)
45. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007;117:2847-59. (Pubitemid 47529615)
46. Tang SC, Arumugam TV, Xu X, Cheng A, Mughal MR, Jo DG, et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc Natl Acad Sci USA 2007;104:13798-803. (Pubitemid 350003400)
47. Oyama J, Blais Jr C, Liu X, Pu M, Kobzik L, Kelly RA, et al. Reduced myocardial ischemiareperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004;109:784-9. (Pubitemid 38222900)
48. Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: Possible route of entry for toxic compounds. Lancet 1984;1:179-82. (Pubitemid 14221988)
49. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218-24.
50. Uesugi T, Froh M, Arteel GE, Bradford BU, Thurman RG. Toll-like receptor 4 is involved in the mechanism of early alcohol-induced liver injury in mice. Hepatology 2001;34:101-8. (Pubitemid 32591488)
51. Kigerl KA, Lai W, Rivest S, Hart RP, Satoskar AR, Popovich PG. Toll-like receptor (TLR)-2 and TLR-4 regulate inflammation, gliosis, and myelin sparing after spinal cord injury. J Neurochem 2007;102:37-50. (Pubitemid 46906264)
52. Babcock AA, Wirenfeldt M, Holm T, Nielsen HH, Dissing-Olesen L, Toft-Hansen H, et al. Toll-like receptor 2 signaling in response to brain injury: An innate bridge to neuroinflammation. J Neurosci 2006;26:12826-37. (Pubitemid 44904578)
53. Kim D, Kim MA, Cho IH, Kim MS, Lee S, Jo EK, et al. A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity. J Biol Chem 2007;282:14975-83. (Pubitemid 47093373)
54. Seki E, Tsutsui H, Iimuro Y, Naka T, Son G, Akira S, et al. Contribution of Toll-like receptor/myeloid differentiation factor 88 signaling to murine liver regeneration. Hepatology 2005;41:443-50. (Pubitemid 40289490)
55. Pull SL, Doherty JM, Mills JC, Gordon JI, Stappenbeck TS. Activated macrophages are an adaptive element of the colonic epithelial progenitor niche necessary for regenerative responses to injury. Proc Natl Acad Sci USA 2005;102:99-104. (Pubitemid 40094435)
56. Campbell JS, Riehle KJ, Brooling JT, Bauer RL, Mitchell C, Fausto N. Proinflammatory cytokine production in liver regeneration is Myd88-dependent, but independent of Cd14, Tlr2, and Tlr4. J Immunol 2006;176:2522-8. (Pubitemid 43201703)
57. Zhang Z, Schluesener HJ. Mammalian toll-like receptors: From endogenous ligands to tissue regeneration. Cell Mol Life Sci 2006;63:2901-7. (Pubitemid 46072297)
58. Pevsner-Fischer M, Morad V, Cohen-Sfady M, Rousso-Noori L, Zanin-Zhorov A, Cohen S, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007;109:1422-32. (Pubitemid 46239573)
59. Hironaka K, Yamaguchi Y, Okita R, Okawaki M, Nagamine I. Essential requirement of toll-like receptor 4 expression on CD11c+ cells for locoregional immunotherapy of malignant ascites using a streptococcal preparation OK-432. Anticancer Res 2006;26:3701-7. (Pubitemid 44701446)
60. Okamoto M, Oshikawa T, Tano T, Ahmed SU, Kan S, Sasai A, et al. Mechanism of anticancer host response induced byOK-432, a streptococcal preparation,mediated by phagocytosis and Toll-like receptor 4 signaling. J Immunother 2006;29:78-86.
61. Uehori J, Fukase K, Akazawa T, Uematsu S, Akira S, Funami K, et al. Dendritic cell maturation induced by muramyl dipeptide (MDP) derivatives: Monoacylated MDP confers TLR2/TLR4 activation. J Immunol 2005;174:7096-103. (Pubitemid 40705675)
62. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair and tumorigenesis. Biochemistry (Mosc) 2008;73:555-61. (Pubitemid 351775078)
63. Salaun B, Coste I, Rissoan MC, Lebecque SJ, Renno T. TLR3 can directly trigger apoptosis in human cancer cells. J Immunol 2006;176:4894-901.
64. El Andaloussi A, Sonabend AM, Han Y, Lesniak MS. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 2006;54:526-35. (Pubitemid 44449333)
65. Haimovitz-Friedman A, Cordon-Cardo C, Bayoumy S, Garzotto M, McLoughlin M, Gallily R, et al. Lipopolysaccharide induces disseminated endothelial apoptosis requiring ceramide generation. J Exp Med 1997;186:1831-41. (Pubitemid 27524593)
66. Nogueras S, Merino A, Ojeda R, Carracedo J, Rodriguez M, Martin-Malo A, et al. Coupling of endothelial injury and repair: An analysis using an in vivo experimental model. Am J Physiol Heart Circ Physiol 2008;294:H708-13.
67. Smyth MJ, Dunn GP, Schreiber RD. Cancer immunosurveillance and immunoediting: The roles of immunity in suppressing tumor development and shaping tumor immunogenicity. Adv Immunol 2006;90:1-50. (Pubitemid 43765795)
68. Akazawa T, Ebihara T, Okuno M, Okuda Y, Shingai M, Tsujimura K, et al. Antitumor NK activation induced by the Toll-like receptor 3-TICAM-1 (TRIF) pathway in myeloid dendritic cells. Proc Natl Acad Sci USA 2007;104:252-7. (Pubitemid 46068018)
69. Chen K, Huang J, Gong W, Iribarren P, Dunlop NM, Wang JM. Toll-like receptors in inflammation, infection and cancer. Int Immunopharmacol 2007;7:1271-85. (Pubitemid 47126372)
70. Pidgeon GP, Harmey JH, Kay E, Da Costa M, Redmond HP, Bouchier-Hayes DJ. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer 1999;81:1311-7.
71. Harmey JH, Bucana CD, Lu W, Byrne AM, McDonnell S, Lynch C, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer 2002;101:415-22.
72. Luo JL, Maeda S, Hsu LC, Yagita H, Karin M. Inhibition of NF-kappaB in cancer cells converts inflammation-induced tumor growth mediated by TNFalpha to TRAIL-mediated tumor regression. Cancer Cell 2004;6:297-305. (Pubitemid 39222042)
73. Huang B, Zhao J, Shen S, Li H, He KL, Shen GX, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Res 2007;67:4346-52. (Pubitemid 46815083)
74. Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, Mènard S, et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006;76:6624-30. (Pubitemid 43787845)
75. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 2007;133:1869-81.
76. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007;317:124-7. (Pubitemid 47056471)
77. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007;317:121-4. (Pubitemid 47056470)
78. Sato Y, Goto Y, Narita N, Hoon DS. Cancer cells expressing Toll-like receptors and the tumor microenvironment. Cancer Microenviron 2009;2(Suppl 1):205-14.
79. Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunol Immunother 2009;5:1375-85.
80. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 2005;6:769-76. (Pubitemid 43090462)
81. Roelofs MF, Joosten LA, Abdollahi-Roodsaz S, van Lieshout AW, Sprong T, van den Hoogen FH, et al. The expression of Toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of Toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum 2005;52:2313-22.
82. Warger T, Osterloh P, Rechtsteiner G, Fassbender M, Heib V, Schmid B, et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006;108:544-50. (Pubitemid 44061354)
83. Gautier G, Humbert M, Deauvieau F, Scuiller M, Hiscott J, Bates EE, et al. A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. J Exp Med 2005;201:1435-46. (Pubitemid 40664087)
84. Theiner G, Rossner S, Dalpke A, Bode K, Berger T, Gessner A, et al. TLR9 cooperates with TLR4 to increase IL-12 release by murine dendritic cells. Mol Immunol 2007;45:244-52. (Pubitemid 47331637)
85. Zhu Q, Egelston C, Vivekanandhan A, Uematsu S, Akira S, Klinman D, et al. Toll-like receptor ligands syner-gize through distinct dendritic cell pathways to induce T cell responses:implications for vaccines. Proc Natl Acad Sci USA 2008;105:16260-5.
86. Krummen M, Balkow S, Shen L, Heinz S, Loquai C, Probst HC, et al. Release of IL-12 by dendritic cells activated by TLR ligation is dependent on MyD88 signaling,whereas TRIF signaling is indispensable for TLR synergy. J Leukoc Biol 2010;88:189-99.
87. Sato S, Nomura F, Kawai T, Takeuchi O, Mühlradt PF, Takeda K, et al. Synergy and cross-tolerance between Toll-like receptor (TLR) 2- and TLR4-mediated signaling pathways. J Immunol 2000;165:7096-101. (Pubitemid 32001184)
88. Ouyang X, Negishi H, Takeda R, Fujita Y, Taniguchi T, Honda K. Cooperation between MyD88 and TRIF pathways in TLR synergy via IRF5 activation. Biochem Biophys Res Commun 2007;354:1045-51. (Pubitemid 46216241)
89. Romagne F. Current and future drugs targeting one class of innate immunity receptors: The Toll-like receptors. Drug Discov Today 2007;12:80-7. (Pubitemid 46014484)
90. Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007;117:1184-94. (Pubitemid 46718403)
91. Krishnan J, Lee G, Choi S. Drugs targeting Toll-like receptors. Arch Pharm Res 2009;32:1485-502.
92. Rossignol DP, Wasan KM, Choo E, Yau E, Wong N, Rose J, et al. Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers. Antimicrob Agents Chemother 2004;48:3233-40.
93. Liu YJ. IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 2005;23:275-306.
94. Lonsdorf AS, Kuekrek H, Stern BV, Boehm BO, Lehmann PV, Tary-Lehmann M. Intratumor CpG-oligodeoxynucleotide injection induces protective antitumor T cell immunity. J Immunol 2003;171:3941-6. (Pubitemid 37238666)
95. Baines J, Celis E. Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides. Clin Cancer Res 2003;9:2693-700. (Pubitemid 36842115)
96. Wooldridge JE, Ballas Z, Krieg AM, Weiner GJ. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood 1997;89:2994-8. (Pubitemid 27172587)
97. Buhtoiarov IN, Lum HD, Berke G, Sondel PM, Rakhmilevich AL. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol 2006;176:309-18. (Pubitemid 43023276)
98. Vicari AP, Chiodoni C, Vaure C, Aït-Yahia S, Dercamp C, Matsos F, et al. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J Exp Med 2002;196:541-9.
99. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005;65:3437-46. (Pubitemid 40524630)
100. Dercamp C, Chemin K, Caux C, Trinchieri G, Vicari AP. Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. Cancer Res 2005;65:8479-86. (Pubitemid 41330616)
101. Davila E, Kennedy R, Celis E. Generation of antitumor immunity by cytotoxic T lymphocyte epitope peptide vaccination, CpG-oligodeoxynucleotide adjuvant, and CTLA4 blockade. Cancer Res 2003;63:3281-8.
102. Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, Diamond DJ, et al. Two distinct pathways of immuno-modulation improve potency of p53 immunization in rejecting established tumors. Cancer Res 2004;64:5407-14. (Pubitemid 39006563)
103. Merad M, Sugie T, Engleman EG, Fong L. In vivo manipulation of dendritic cells to induce therapeutic immunity. Blood 2002;99:1676-82.
104. Okano F, Merad M, Furumoto K, Engleman EG. In vivo manipulation of dendritic cells overcomes tolerance to unmodified tumorassociated self antigens and induces potent antitumor immunity. J Immunol 2005;174:2645-52.
105. Ishii KJ, Kawakami K, Gursel I, Conover J, Joshi BH, Klinman DM, et al. Antitumor therapy with bacterial DNA and toxin: Complete regression of established tumor induced by liposomal CpG oligodeoxynucleotides plus interleukin-13 cytotoxin. Clin Cancer Res 2003;9:6516-22. (Pubitemid 38031840)
106. Chaudhry UI, Kingham TP, Plitas G, Katz SC, Raab JR, DeMatteo RP. Combined stimulation with interleukin-18 and CpG induces murine natural killer dendritic cells to produce IFN-gamma and inhibit tumor growth. Cancer Res 2006;66: 10497-504. (Pubitemid 44799771)
107. Whitmore MM, DeVeer MJ, Edling A, Oates RK, Simons B, Lindner D, et al. Synergistic activation of innate immunity by double-stranded RNA and CpG DNA promotes enhanced antitumor activity. Cancer Res 2004;64:5850-60. (Pubitemid 39095586)
108. Sfondrini L, Rossini A, Besusso D, Merlo A, Tagliabue E, Mènard S, et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J Immunol 2006;176:6624-30. (Pubitemid 43787845)
109. Damiano V, Caputo R, Bianco R, D'Armiento FP, Leonardi A, De Placido S, et al. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors. Clin Cancer Res 2006;2006(12):577-83. (Pubitemid 43166152)
110. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting Toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005;11:361-9. (Pubitemid 40075816)
111. Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003;9:3105-14. (Pubitemid 36993273)
112. Ohashi K, Kobayashi G, Fang S, Zhu X, Antonia SJ, Krieg AM, et al. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J Pediatr Surg 2006;41:1361-8. (Pubitemid 44080244)
113. den Brok MH, Sutmuller RP, Nierkens S, Bennink EJ, Toonen LW, Figdor CG, et al. Synergy between in situ cryoablation and TLR9 stimulation results in a highly effective in vivo dendritic cell vaccine. Cancer Res 2006;66:7285-92. (Pubitemid 44197710)
114. Taieb J, Chaput N, Schartz N, Roux S, Novault S, Ménard C, et al. Chemoimmunotherapy of tumors: Cyclophosphamide synergizes with exosome based vaccines. J Immunol 2006;176:2722-9.
115. Balsari A, Tortoreto M, Besusso D, Petrangolini G, Sfondrini L, Maggi R, et al. Combination of a CpG-oligodeoxynucleotide and a topoisomerase I inhibitor in the therapy of human tumour xenografts. Eur J Cancer 2004;40:1275-81. (Pubitemid 38526349)
116. Wang XS, Sheng Z, Ruan YB, Guang Y, Yang ML. CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma. World J Gastroenterol 2005;11:1220-4. (Pubitemid 40357652)
117. Pratesi G, Petrangolini G, Tortoreto M, Addis A, Belluco S, Rossini A, et al. Therapeutic synergismof gemcitabine and CpG-oligodeoxynucleotides in an orthotopic human pancreatic carcinoma xenograft. Cancer Res 2005;65:6388-93. (Pubitemid 40994426)
118. Wang H, Rayburn ER, Wang W, Kandimalla ER, Agrawal S, Zhang R. Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Mol Cancer Ther 2006;5:1585-92. (Pubitemid 44070496)
119. van der Most RG, Himbeck R, Aarons S, Carter SJ, Larma I, Robinson C, et al. Antitumor efficacy of the novel chemotherapeutic agent coramsine is potentiated by cotreatment with CpG-containing oligodeoxynucleotides. J Immunother 2006;29:134-42.
120. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 2004;303:1526-9. (Pubitemid 38314424)
121. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004;303:1529-31.
122. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 2002;3:196-200. (Pubitemid 34141451)
123. Lee J, Chuang TH, Redecke V, She L, Pitha PM, Carson DA, et al. Molecular basis for the immunostimulatory activity of guanine nucleoside analogs: Activation of Toll-like receptor 7. Proc Natl Acad Sci USA 2003;100:6646-51. (Pubitemid 36666635)
124. Harrison CJ, Jenski L, Voychehovski T, Bernstein DI. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. Antivir Res 1988;10:209-23.
125. Akira S, Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003;85:85-95. (Pubitemid 36071561)
126. Sidky YA, Borden EC, Weeks CE, Reiter MJ, Hatcher JF, Bryan GT. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. Cancer Res 1992;52:3528-33.
127. Rechtsteiner G, Warger T, Osterloh P, Schild H, Radsak MP. Cutting edge: Priming of CTL by transcutaneous peptide immunization with imiquimod. J Immunol 2005;174:2476-80. (Pubitemid 40279657)
128. Prins RM, Craft N, Bruhn KW, Khan-Farooqi H, Koya RC, Stripecke R, et al. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J Immunol 2006;176:157-64. (Pubitemid 43023259)
129. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007;204:1441-51. (Pubitemid 46919881)
130. Schön MP, Schön M. TLR7 and TLR8 as targets in cancer therapy. Oncogene 2008;27:190-9.
131. Coley toxins detailed scientific review, in the Web site of MD Anderson Cancer Center, The University of Texas. http://www.mdanderson.org/education-and- research/resources-for-professionals/clinical-tools-and-resources/cimer/ therapies/nonplantbiologic-organic-pharmacologic-therapies/coley-toxins- scientific.html.
132. Official site of the Maruyama vaccine, in the Web site of the Research Institute of Vaccine Therapy for Tumors and Infectious Diseases, Nippon Medical School (in Japanese). http://www.mdanderson.org/education-and-research/index. html
133. ClinicalTrials.gov, Web site for a service of the U. S. National Institutes of Health. http://www.clinicaltrials.gov/ct2/home.